A retrospective, multicentre, observational study to assess real-life outcomes in AML patients receiving CPX-351 in Italian hematological centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie)
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 04 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association